EI

263

-1.31%↓

MRK1

108

-0.18%↓

SHL.DE

47.28

-0.21%↓

ARGX

603.2

-0.66%↓

FRE

46.21

-1.2%↓

EI

263

-1.31%↓

MRK1

108

-0.18%↓

SHL.DE

47.28

-0.21%↓

ARGX

603.2

-0.66%↓

FRE

46.21

-1.2%↓

EI

263

-1.31%↓

MRK1

108

-0.18%↓

SHL.DE

47.28

-0.21%↓

ARGX

603.2

-0.66%↓

FRE

46.21

-1.2%↓

EI

263

-1.31%↓

MRK1

108

-0.18%↓

SHL.DE

47.28

-0.21%↓

ARGX

603.2

-0.66%↓

FRE

46.21

-1.2%↓

EI

263

-1.31%↓

MRK1

108

-0.18%↓

SHL.DE

47.28

-0.21%↓

ARGX

603.2

-0.66%↓

FRE

46.21

-1.2%↓

Search

Sanofi SA

Geschlossen

BrancheGesundheitswesen

85.4 -1.42

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

85.27

Max

86.62

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.1B

2.9B

Verkäufe

129M

11B

KGV

Branchendurchschnitt

16.75

35.724

EPS

1.59

Dividendenrendite

4.49

Gewinnspanne

27.303

Angestellte

82,878

EBITDA

-881M

1.9B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+22.92% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.49%

3.09%

Nächstes Ergebnis

24. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.2B

105B

Vorheriger Eröffnungskurs

86.82

Vorheriger Schlusskurs

85.4

Nachrichtenstimmung

By Acuity

31%

69%

74 / 372 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Sanofi SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Aug. 2025, 10:06 UTC

Wichtige Markttreiber

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

31. Juli 2025, 06:00 UTC

Ergebnisse

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

30. Juli 2025, 10:20 UTC

Ergebnisse

Santander Reports Higher Profit, but Regional Picture is Mixed -- Update

30. Juli 2025, 05:31 UTC

Ergebnisse

Santander Sticks to Guidance, Launches $2 Billion Buyback After Profit Rises

6. Aug. 2025, 05:02 UTC

Akquisitionen, Fusionen, Übernahmen

Sanofi Completes the Acquisition of Vigil Neuroscience

6. Aug. 2025, 05:00 UTC

Akquisitionen, Fusionen, Übernahmen

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1. Aug. 2025, 13:16 UTC

Ergebnisse

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1. Aug. 2025, 12:40 UTC

Ergebnisse

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31. Juli 2025, 08:15 UTC

Market Talk
Ergebnisse

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31. Juli 2025, 05:56 UTC

Market Talk
Ergebnisse

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi 2Q Business Operating Profit EUR2.46B

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi 2Q Adj EPS EUR1.59

31. Juli 2025, 05:30 UTC

Ergebnisse

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

31. Juli 2025, 05:30 UTC

Ergebnisse

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi 2Q Net Pft EUR3.94B

31. Juli 2025, 05:30 UTC

Ergebnisse

Analysts Saw Sanofi 2Q Business EPS at EUR1.64

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi Now Expects 2025 Sales Growth at Constant Currency at High Single-Digit Percentage

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi Had Seen 2025 Sales Growth at Constant Currency at Mid-To-High Single-digit

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi 2Q Sales EUR9.99B

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi Backs 2025 EPS Adj View

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi Narrows 2025 Sales View

31. Juli 2025, 05:30 UTC

Ergebnisse

Sanofi Confirms Expectations of Business EPS Rebound in 2025 Before Buybacks

30. Juli 2025, 07:48 UTC

Market Talk
Ergebnisse

Santander Results Get Lukewarm Reaction -- Market Talk

30. Juli 2025, 06:41 UTC

Market Talk
Ergebnisse

Santander's Strategic Investments in Focus -- Market Talk

30. Juli 2025, 04:52 UTC

Ergebnisse

Santander End-2Q CET1 Ratio 13%

Peer-Vergleich

Kursveränderung

Sanofi SA Prognose

Kursziel

By TipRanks

22.92% Vorteil

12-Monats-Prognose

Durchschnitt 106.053 EUR  22.92%

Hoch 124 EUR

Tief 81.658 EUR

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sanofi SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

14 ratings

10

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

91.3 / 96.1Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

74 / 372 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.